注射免疫疗法显示了对于肝脏肿瘤的希望

StephenW

Injectable immunotherapy shows promise for liver tumors
March 22, 2018

Talimogene laherparevec, a genetically modified version of the herpes virus, was well-tolerated after injection into active cancer in the liver and stimulated patient immune systems to destroy cancer cells throughout the body, according to a press release and presentation at the Society of Interventional Radiology Annual Scientific Meeting.

“Advanced stage liver tumors, including ones that have spread from other locations, have limited treatment options because the patients can be in poor health; further, the complex structure of the organ can make it difficult to target with standard approaches,” Steven S. Raman, MD, from the David Geffen School of Medicine, University of California, and lead study author said in the press release. “This minimally invasive treatment offers patients a novel way to directly and indirectly attack the cancer cells.”

Talimogene laherparevec (T-VEC, Amgen) is a genetically modified HSV-1 oncolytic immunotherapy designed to preferentially replicate in tumors and produce granulocyte-macrophage colony-stimulating factor to stimulate anti-tumor immune responses.

Fourteen patients with either hepatocellular carcinoma or liver metastases related to extrahepatic cancer received T-VEC every 21 days up to the maximum tolerated concentration of 108 plague-forming units per mL.

One patient underwent liver transplantation and three patients had a significant increase in aspartate aminotransferase and bilirubin after one dose. Four patients had grade 3 or 4 treatment-related adverse events. Two patients died and both were attributable to disease.

The researchers deemed the intralesional injection of T-VEC as tolerable and feasible in patients with liver cancer and metastases. They further report planning an additional investigation in combination with a PD-1 inhibitor.

“Image-guided treatments have expanded the options available for patients with liver cancer from innovative approaches to biopsies to resections to chemo,” Raman said in the release. “This is an exciting way to look to the future, but patients living with advanced liver cancer should understand that this treatment will not be available for several years, except through clinical trials.” – by Talitha Bennett



Reference: Raman SS. Abstract 375. Presented at: Society of Interventional Radiology Annual Scientific Meeting; Mar. 17-22, 2018; Los Angeles.



Disclosure: The authors report that the pharmaceutical manufacturer of T-VEC, Amgen, was a sponsor of the trial.

StephenW

注射免疫疗法显示了对于肝脏肿瘤的希望
2018年3月22日

根据介绍性放射学会的新闻稿和介绍，Talimogene laherparevec是一种经过遗传修饰的疱疹病毒，在注射到肝脏中的活跃癌症中并且刺激了患者的免疫系统以摧毁整个身体的癌细胞后，具有良好的耐受性年度科学会议。

“晚期肝脏肿瘤，包括从其他地方传播的肝肿瘤，治疗方案有限，因为患者的健康状况很差;此外，器官的复杂结构可能难以用标准方法进行靶向，“加利福尼亚大学David Geffen医学院的Steven S. Raman医师和主要研究作者在新闻稿中说。 “这种微创治疗为患者提供了直接和间接攻击癌细胞的新途径。”

Talimogene laherparevec（T-VEC，Amgen）是一种基因修饰的HSV-1溶瘤免疫疗法，设计用于在肿瘤中优先复制并产生粒细胞 - 巨噬细胞集落刺激因子以刺激抗肿瘤免疫应答。

肝细胞癌或与肝外癌相关的肝转移的14例患者每隔21天接受一次T-VEC，直至最大耐受浓度达到每毫升108个鼠疫形成单位。

一名患者接受了肝移植，三名患者在一次给药后天冬氨酸转氨酶和胆红素显着增加。 4名患者有3或4级治疗相关不良事件。两名患者死亡，都是由于疾病。

研究人员认为病灶内注射T-VEC对于肝癌和转移患者是可以忍受和可行的。他们进一步报告计划与PD-1抑制剂联合进行额外的调查。

拉曼在发布会上说：“图像引导治疗已经扩展了肝癌患者的创新方法，从活检到切除到化疗的可用选项。” “这是一个展望未来的令人兴奋的方式，但患有晚期肝癌的患者应该明白，除了通过临床试验外，这种治疗方法将在几年内无法使用。” -  Talitha Bennett



参考：拉曼SS。摘要375.介绍：介入放射学协会年度科学会议; 2018年3月17  -  22日;洛杉矶。



披露：作者报告说，T-VEC的制药商Amgen是该试验的赞助商。